everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...6465666768697071727374...132133»
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] [18F]FDG-PET/CT AND LONG-TERM RESPONSE TO EVEROLIMUS IN ADVANCED NEUROENDOCRINE NEOPLASIA (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_5142;    
    Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NENs, even in those patients with positive FDG-PET. Physicians should be reassured not to debarring patients of the everolimus therapeutic option basing on the sole positivity of this imaging procedure, since it remains a valid treatment with relevant probability to achieve long-term disease control over time, particularly in G1 and G2 NENs with low SUV at FDG-PET.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] [18F]FDG-PET/CT AND LONG-TERM RESPONSE TO EVEROLIMUS IN ADVANCED NEUROENDOCRINE NEOPLASIA (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_3166;    
    Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NENs, even in those patients with positive FDG-PET. Physicians should be reassured not to debarring patients of the everolimus therapeutic option basing on the sole positivity of this imaging procedure, since it remains a valid treatment with relevant probability to achieve long-term disease control over time, particularly in G1 and G2 NENs with low SUV at FDG-PET.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] [18F]FDG-PET/CT AND LONG-TERM RESPONSE TO EVEROLIMUS IN ADVANCED NEUROENDOCRINE NEOPLASIA (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_1182;    
    Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NENs, even in those patients with positive FDG-PET. Physicians should be reassured not to debarring patients of the everolimus therapeutic option basing on the sole positivity of this imaging procedure, since it remains a valid treatment with relevant probability to achieve long-term disease control over time, particularly in G1 and G2 NENs with low SUV at FDG-PET.
  • ||||||||||  everolimus / Generic mfg.
    Retrospective data, Review, Journal:  Management of carcinoid syndrome: a systematic review and meta-analysis. (Pubmed Central) -  Jul 18, 2020   
    We conclude that several treatment lines can be offered to patients suffering from the carcinoid syndrome. Initiation of randomized controlled trials with a primary outcome on carcinoid syndrome symptoms is strongly recommended.
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Journal:  mTOR-induced pneumonitis in a 72-year-old patient after heart transplantation (Pubmed Central) -  Jul 18, 2020   
     Everolimus-related interstitial pneumonitis represents a rare but important adverse effect of everolimus in immunosuppressed patients. Recognition of everolimus induced pneumonitis is of high clinical relevance and should be considered in all patients on everolimus presenting with respiratory symptoms of unknown origin.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors (Pubmed Central) -  Jul 18, 2020   
    Despite the identification of multiple molecular mechanisms of resistance, no predictive biomarker has made it to the clinic. This review is focused on the mTOR signaling and angiogenesis in NET, the molecular mechanisms of primary and acquired resistance to everolimus and sunitinib and how to overcome this resistance by alternative drug compounds.
  • ||||||||||  Avastin (bevacizumab) / Roche, everolimus / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor. (Pubmed Central) -  Jul 17, 2020   
    Regrown tumors were treated based on mutations (palbociclib and JQ1), drug availability, and published literature (nab-paclitaxel; bevacizumab; sorafenib plus doxorubicin; and gemcitabine plus docetaxel)...Our results indicate the feasibility of generating MPNST-PDOX and genomic characterization to guide treatment in real time. Although the treatment responses observed in our model did not fully recapitulate the patient's response, this pilot study identify key aspects to improve our co-clinical testing approach in real time.
  • ||||||||||  cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
    Trial completion date, Trial primary completion date:  LITMMUS-UCSF: Liver Transplantation With Tregs at UCSF (clinicaltrials.gov) -  Jul 16, 2020   
    P1/2,  N=9, Not yet recruiting, 
    Although the treatment responses observed in our model did not fully recapitulate the patient's response, this pilot study identify key aspects to improve our co-clinical testing approach in real time. Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
  • ||||||||||  veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
    Enrollment closed, Metastases:  MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) -  Jul 16, 2020   
    P2,  N=700, Active, not recruiting, 
    Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027 Recruiting --> Active, not recruiting
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial primary completion date:  Treg Modulation With CD28 and IL-6 Receptor Antagonists (clinicaltrials.gov) -  Jul 16, 2020   
    P1/2,  N=10, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Apr 2021 --> Jun 2022
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Co-administration of everolimus and N-acetylcysteine attenuates hepatic stellate cell activation and hepatic fibrosis. (Pubmed Central) -  Jul 15, 2020   
    Moreover, in vivo studies showed that everolimus inhibited collagen deposition and inflammation in a mouse model of fibrogenesis, as determined by histological analysis, and everolimus treatment, in combination with NAC, significantly decreased extracellular matrix deposition and improved liver histology. These findings indicated that everolimus, combined with NAC, synergistically inhibited hepatic fibrosis and thus may become a valuable option in immunosuppressant therapy.
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] Real life experience in mTOR-inhibitors after lung transplantation (Channel 3) -  Jul 15, 2020 - Abstract #ERS2020ERS_4799;    
    Results Of 676 LTR currently in follow-up, 111 (16.4%) received a mTORi (2 sirolimus, rest everolimus)...Myelotoxicity (3.5%) and gastrointestinal intolerance (12.3%) were less frequently than expected the cause of discontinuation, presumably because LTR more susceptible to these side-effects were not initiated on mTORi. Conclusion mTORi had to be stopped due to adverse events or intolerance in 43.2% of LTR, suggesting that cautious consideration of advantages and disadvantages when starting mTORi is needed.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Jul 14, 2020   
    P1,  N=15, Recruiting, 
    In conclusion HA decorated LIP are promising biocompatible nanovectors and open the possibility to use everolimus as inhalatory targeted therapy for ILD patients increasing the bioavailability of drug. Suspended --> Recruiting
  • ||||||||||  Journal:  New therapeutic approaches for endometriosis besides hormonal therapy. (Pubmed Central) -  Jul 10, 2020   
    Clinical data about most of the non-hormonal agents are not sufficient to support them as options for replacement therapy for endometriosis. In spite of this, a few drugs like pentoxifylline showed strong potential for real clinical application.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Clinical, Journal:  RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma. (Pubmed Central) -  Jul 10, 2020   
    Noteworthy, knocking-down stably RICTOR significantly suppresses RAD001-induced feedback activation of AKT/PRAS40 signaling, and enhances inhibition efficacy of PP242 on the phosphorylation of AKT and PRAS40, thus potentiates the antitumor effect of RAD001 and PP242 both in vitro and in vivo. Our findings highlight that selective targeting mTORC2 could be a promising therapeutic strategy for future treatment of ESCC.
  • ||||||||||  Afinitor (everolimus) / Novartis, sirolimus / Generic mfg.
    Clinical, Retrospective data, Journal:  mTOR inhibitors in pediatric liver transplant recipients. (Pubmed Central) -  Jul 7, 2020   
    Our data suggest that the combination of fingolimod with the established NSCLC/ovarian cancer drug pemetrexed should be explored as a new therapy. Our results suggest that mTORi can be used in pediatric LT recipients in different clinical situations, both to reinforce immunosuppressive therapy, and to reduce CNI and related toxicity.
  • ||||||||||  Zokinvy (lonafarnib) / Eiger
    Enrollment status, Combination therapy:  Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria (clinicaltrials.gov) -  Jul 7, 2020   
    P1/2,  N=80, Enrolling by invitation, 
    Our results suggest that mTORi can be used in pediatric LT recipients in different clinical situations, both to reinforce immunosuppressive therapy, and to reduce CNI and related toxicity. Recruiting --> Enrolling by invitation
  • ||||||||||  everolimus / Generic mfg.
    [VIRTUAL] False Positive 68 Ga-DOTATATE PET/CT in a Patient with Small Bowel Carcinoid Tumor (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_6229;    
    Octreotide was discontinued and everolimus was initiated for presumed disease progression however, after two weeks, everolimus was discontinued due to associated drug fever...He was treated with itraconazole and at six month follow-up, symptoms had significantly improved and adenopathy had decreased...In our patient, Cryptococcus infection was not suspected however, the low avidity that was substantially lower than the primary tumor was an indication that this was an alternative process rather than metastatic disease. Clinicians need to keep these pitfalls in mind and consider alternative processes which may lead to change in management.
  • ||||||||||  doxycycline / Generic mfg., Pierre Fabre, everolimus / Generic mfg.
    [VIRTUAL] A Rare Case of Everolimus Induced Organizing Pneumonia (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_4174;    
    Everolimus is used to treat angiomyolipomas in patients with tuberous sclerosis complex. Rarely, it can cause organizing pneumonia which can be treated with discontinuation of the medication and oral corticosteroids.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  Antimycobacterial Effects of Everolimus in a Human Granuloma Model. (Pubmed Central) -  Jul 3, 2020   
    This study has shown that everolimus is a promising host-directed therapeutic in the context of in vitro granuloma M. tb infection. Further study is warranted to better characterize these effects.
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer (clinicaltrials.gov) -  Jul 2, 2020   
    P2,  N=41, Active, not recruiting, 
    Real-world PFS and tolerability were similar to clinical studies of pazopanib. Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial initiation date:  Mobile Application to Collect PRO Data in NET Patients (clinicaltrials.gov) -  Jun 30, 2020   
    P=N/A,  N=2000, Not yet recruiting, 
    Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Initiation date: Apr 2020 --> Jul 2020
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  Proteomic analysis of stromal and epithelial cell communications in human endometrial cancer using a unique 3D co-culture model. (Pubmed Central) -  Jun 29, 2020   
    To determine the feasibility of using this model for drug screening, we tested the efficacy of tamoxifen and everolimus. In summary, we have developed a unique 3D model system of human endometrial cancer that will serve as the foundation for the further development of 3D culture systems incorporating different cell types of the human uterus for deciphering the contributions of non-epithelial cells present in cancer microenvironment.